{"id":"NCT01231321","sponsor":"Abbott","briefTitle":"A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis","officialTitle":"An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (HumiraÂ®) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2010-11-01","resultsPosted":"2011-03-24","lastUpdate":"2011-04-26"},"enrollment":100,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"adalimumab","type":"EXPERIMENTAL"}],"summary":"A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5 sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with dose escalation to weekly dosing available for participants not receiving concomitant disease-modifying antirheumatic drugs (DMARDs) who did not achieve American College of Rheumatology 20 (ACR20) criteria after 12 weeks of treatment. Efficacy and safety measurements were performed throughout the study.","primaryOutcome":{"measure":"Frequency of Adverse Events","timeFrame":"Up to 34 weeks (24 week study treatment plus 70-day follow-up period)","effectByArm":[{"arm":"Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL","deltaMin":38,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":100},"commonTop":["Nasopharyngitis","Respiratory disorder","Headache","Injection site erythema","Osteochondrosis"]}}